Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SafE-OrBi: Switching from Humira to Imraldi in inflammatory bowel disease
2019-002041-38Phase 4Completed
- Sponsor
- AZ Maria Middelares
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by AZ Maria Middelares. Primary endpoint: Adalimumab trough level at baseline (transition). Started Jun 2019; status: completed.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2019-002041-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002041-38.